Margaret Marcon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Margaret Marcon has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
É Drouin
Canadian Pediatric EoE Network,
1 shared publicationA Chung
University of Alberta , Edmonton
1 shared publicationA Martinez
Canadian Pediatric EoE Network,
1 shared publicationAimee C. Pastor
1 shared publication- Allan Puran1 shared publication
- Alyssa V. Ramuscak
The Hospital for Sick Children, Department of Pediatrics, Division of Gastroenterology, Hepatology & Nutrition, Toronto, Ontario, Canada
1 shared publication
Latest Publications
- Open Access
- 25 September 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Development of a Patient-Reported Outcome Instrument for Children and Youth With Celiac Disease (CELIAC-Q Kids): Protocol for an International Phase 1 Mixed Methods Study (Preprint)
BACKGROUND A critical limitation in outcome assessment for celiac disease (CeD) is the lack of a pediatric-specific patient-reported outcome (PRO) instrument to capture disease- and treatment-related outcomes and experiences of health and health care from the patient perspective. OBJECTIVE This protocol describes phase 1 of a multiphase mixed methods study to develop the CELIAC-Q Kids, a cross-cultural, internationally applicable PRO instrument for children and youth aged 8 to 18 years with CeD. METHODS The CELIAC-Q Kids will be developed using a multistage mixed methods approach consistent with best practices for PRO instrument development. First, a scoping review identifying concepts previously measured in individuals with CeD informed the development of a preliminary conceptual framework. Second, concept elicitation interviews with children and youth aged 8 to 18 years with CeD and their caregivers will be conducted to identify concepts of importance to patients. Qualitative data will be analyzed using interpretive description to refine the conceptual framework and generate an item pool and preliminary scales. Third, cognitive debriefing interviews with children and youth, together with multidisciplinary expert clinician input from participating international centers, will be used to iteratively refine items and scales. Finally, the field-test version of the CELIAC-Q Kids will be translated using rigorous, standardized methods in preparation for an international field-test study. Ethics approval has been obtained from the research ethics boards at all participating sites. RESULTS The study was first funded in 2020, with additional funding received in 2025. Recruitment for the concept elicitation interviews began in July 2020, and data collection was completed in June 2024 with 25 participants. As of September 2026, cognitive debriefing interviews are ongoing. The field-test version of the CELIAC-Q Kids is expected to be complete by December 2026, translation and cultural adaptation are planned for 2027, and phase 1 results are expected to be published in 2027 CONCLUSIONS At the end of this phase, a conceptual framework and set of scales capturing disease- and treatment-related outcomes and experiences relevant to pediatric CeD will be developed and ready for field testing. An integrated knowledge translation approach will engage patients, families, and clinicians throughout the study, and findings will be disseminated through peer-reviewed publications and scientific conferences. CLINICALTRIAL ClinicalTrials.gov NCT05548166
- 25 September 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDevelopment of a Patient-Reported Outcome Instrument for Children and Youth With Celiac Disease (CELIAC-Q Kids): Protocol for an International Phase 1 Mixed Methods Study (Preprint)
BACKGROUND A critical limitation in outcome assessment for celiac disease (CeD) is the lack of a pediatric-specific patient-reported outcome (PRO) instrument to capture disease- and treatment-related outcomes and experiences of health and health care from the patient perspective. OBJECTIVE This protocol describes phase 1 of a multiphase mixed methods study to develop the CELIAC-Q Kids, a cross-cultural, internationally applicable PRO instrument for children and youth aged 8 to 18 years with CeD. METHODS The CELIAC-Q Kids will be developed using a multistage mixed methods approach consistent with best practices for PRO instrument development. First, a scoping review identifying concepts previously measured in individuals with CeD informed the development of a preliminary conceptual framework. Second, concept elicitation interviews with children and youth aged 8 to 18 years with CeD and their caregivers will be conducted to identify concepts of importance to patients. Qualitative data will be analyzed using interpretive description to refine the conceptual framework and generate an item pool and preliminary scales. Third, cognitive debriefing interviews with children and youth, together with multidisciplinary expert clinician input from participating international centers, will be used to iteratively refine items and scales. Finally, the field-test version of the CELIAC-Q Kids will be translated using rigorous, standardized methods in preparation for an international field-test study. Ethics approval has been obtained from the research ethics boards at all participating sites. RESULTS The study was first funded in 2020, with additional funding received in 2025. Recruitment for the concept elicitation interviews began in July 2020, and data collection was completed in June 2024 with 25 participants. As of September 2026, cognitive debriefing interviews are ongoing. The field-test version of the CELIAC-Q Kids is expected to be complete by December 2026, translation and cultural adaptation are planned for 2027, and phase 1 results are expected to be published in 2027 CONCLUSIONS At the end of this phase, a conceptual framework and set of scales capturing disease- and treatment-related outcomes and experiences relevant to pediatric CeD will be developed and ready for field testing. An integrated knowledge translation approach will engage patients, families, and clinicians throughout the study, and findings will be disseminated through peer-reviewed publications and scientific conferences. CLINICALTRIAL ClinicalTrials.gov NCT05548166
- Open Access
- 7 January 2026
- Published by Taylor & Francis in Gut Microbes
- Vol. 18 (1) , 2610597
The role of gut microbiota in chronic intestinal pseudo-obstruction: exploring fecal microbiota transplantation as a treatment option
Chronic intestinal pseudo-obstruction (CIPO) is characterized by bowel dilation and obstructive symptoms without any structural blockage. Although the microbiota is known to affect gastrointestinal function, its role in CIPO is poorly understood. We aimed to characterize the CIPO microbiota, investigate its role in disease expression and explore the therapeutic role of fecal microbiota transplantation (FMT). CIPO patients (n = 14) and healthy controls (HC, n = 12) were recruited from Italy and Canada. Microbiota profiles and functions were assessed by 16S rRNA sequencing and PICRUSt. Germ-free NIH Swiss mice were colonized with HC and CIPO microbiota, their intestinal transit and bowel distension were assessed by videofluoroscopy and computed tomography (CT), and the expression of host genes by NanoString®. The CIPO microbiota exhibited reduced microbial diversity with dominance of Proteobacteria and altered metabolic function. Mice with CIPO microbiota developed marked bowel distension and slow intestinal transit associated with altered expression of multiple genes related to immunity, the intestinal barrier and neuromuscular function. FMT from a HC improved the microbiota profile, intestinal transit and bowel distension in both CIPO mice and a selected CIPO patient, in whom a marked clinical improvement was sustained for 8 y. Thus, our findings support the use of microbiota-directed therapies to induce clinical improvement in CIPO patients.
- 7 January 2026
- Published by Taylor & Francis in Gut Microbes
- Vol. 18 (1) , 2610597
Open AccessThe role of gut microbiota in chronic intestinal pseudo-obstruction: exploring fecal microbiota transplantation as a treatment option
Chronic intestinal pseudo-obstruction (CIPO) is characterized by bowel dilation and obstructive symptoms without any structural blockage. Although the microbiota is known to affect gastrointestinal function, its role in CIPO is poorly understood. We aimed to characterize the CIPO microbiota, investigate its role in disease expression and explore the therapeutic role of fecal microbiota transplantation (FMT). CIPO patients (n = 14) and healthy controls (HC, n = 12) were recruited from Italy and Canada. Microbiota profiles and functions were assessed by 16S rRNA sequencing and PICRUSt. Germ-free NIH Swiss mice were colonized with HC and CIPO microbiota, their intestinal transit and bowel distension were assessed by videofluoroscopy and computed tomography (CT), and the expression of host genes by NanoString®. The CIPO microbiota exhibited reduced microbial diversity with dominance of Proteobacteria and altered metabolic function. Mice with CIPO microbiota developed marked bowel distension and slow intestinal transit associated with altered expression of multiple genes related to immunity, the intestinal barrier and neuromuscular function. FMT from a HC improved the microbiota profile, intestinal transit and bowel distension in both CIPO mice and a selected CIPO patient, in whom a marked clinical improvement was sustained for 8 y. Thus, our findings support the use of microbiota-directed therapies to induce clinical improvement in CIPO patients.
- Open Access
- 1 March 2023
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 6 (Supplement) , 1-2
A150 MODERATE AGREEMENT IN ENDOSCOPIC DISEASE SCORING OF PEDIATRIC EOSINOPHILIC ESOPHAGITIS AMONG PEDIATRIC GASTROENTEROLOGISTS IN CANADA
Endoscopy is an important tool in assessing the severity of gastrointestinal diseases including Eosinophilic Esophagitis (EoE). Agreement regarding endoscopy outcomes is important when using tools such as the Endoscopic Reference Score for EoE (EREFS). Our goal was to determine interrater and intrarater agreement of EREFS among Canadian pediatric gastroenterologists. Survey-based study of interrater and intrarater reliability amongst pediatric gastroenterologists with interest in pediatric EoE. Participants were sourced from the Canadian Pediatric EoE Network. Participants were asked how many years of training they’ve had with endoscopy for pediatric EoE and their comfort in disease scoring for pediatric EoE. Pediatric EoE cases were identified from the pediatric EoE registry at the Stollery Children’s Hospital with an endoscopic video associated with each case. Participants were asked to score each video using the EREFS questionnaire for the proximal, middle and distal segments of the esophagus. 15 endoscopic videos were evaluated, with 3 cases provided each week over a period of 5 weeks. Additional data included ratings of the video quality and endoscopy quality. Of 15 cases, 12 were unique cases, distributed evenly in severity between no active disease to severe disease. 3 cases were repeated to assess intrarater reliability. The maximum grade of the proximal, middle and distal segments of the esophagus for each component endoscopic finding (edema, rings, exudates, furrows, strictures) were used for reliability calculations. Fleiss Kappa was calculated for all EREFS items and for each component endoscopic finding. Cohen’s Kappa was calculated to assess intrarater reliability. Fifteen participants were recruited for the study. The participants had a median of 12 years (IQR: 7, 19) of clinical experience in endoscopy for pediatric EoE. The majority of participants were “comfortable” (i.e., 4 on 5-point scale) with EREFS scoring for pediatric EoE. Fleiss Kappa for all EREFS items was 0.481. For each component endoscopic finding (edema, rings, exudates, furrows, strictures), Fleiss Kappa was 0.365, 0.293, 0.548, 0.263, 0.445 respectively. Cohen’s Kappa had a median of 0.620 (IQR: 0.593, 0.704). The majority of raters rated video quality and endoscopy quality as “good” (i.e., 4 on 5-point scale). There is moderate interrater reliability in EREFS scoring for pediatric EoE. Interrater reliability was between fair to moderate for each component endoscopic finding. Intrarater reliability was good. This study shows there is room for improvement in disease scoring for pediatric EoE. This could be in the form of additional training, expert-defined conventions, or centralized reading which have reduced variability in endoscopic reporting for adult GI disease in past studies and could be used in a follow-up study to attempt to improve agreement. Additionally, incorporating EREFS into routine clinical practice may increase agreement amongst endoscopists. None None Declared
- 1 March 2023
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 6 (Supplement) , 1-2
Open AccessA150 MODERATE AGREEMENT IN ENDOSCOPIC DISEASE SCORING OF PEDIATRIC EOSINOPHILIC ESOPHAGITIS AMONG PEDIATRIC GASTROENTEROLOGISTS IN CANADA
Endoscopy is an important tool in assessing the severity of gastrointestinal diseases including Eosinophilic Esophagitis (EoE). Agreement regarding endoscopy outcomes is important when using tools such as the Endoscopic Reference Score for EoE (EREFS). Our goal was to determine interrater and intrarater agreement of EREFS among Canadian pediatric gastroenterologists. Survey-based study of interrater and intrarater reliability amongst pediatric gastroenterologists with interest in pediatric EoE. Participants were sourced from the Canadian Pediatric EoE Network. Participants were asked how many years of training they’ve had with endoscopy for pediatric EoE and their comfort in disease scoring for pediatric EoE. Pediatric EoE cases were identified from the pediatric EoE registry at the Stollery Children’s Hospital with an endoscopic video associated with each case. Participants were asked to score each video using the EREFS questionnaire for the proximal, middle and distal segments of the esophagus. 15 endoscopic videos were evaluated, with 3 cases provided each week over a period of 5 weeks. Additional data included ratings of the video quality and endoscopy quality. Of 15 cases, 12 were unique cases, distributed evenly in severity between no active disease to severe disease. 3 cases were repeated to assess intrarater reliability. The maximum grade of the proximal, middle and distal segments of the esophagus for each component endoscopic finding (edema, rings, exudates, furrows, strictures) were used for reliability calculations. Fleiss Kappa was calculated for all EREFS items and for each component endoscopic finding. Cohen’s Kappa was calculated to assess intrarater reliability. Fifteen participants were recruited for the study. The participants had a median of 12 years (IQR: 7, 19) of clinical experience in endoscopy for pediatric EoE. The majority of participants were “comfortable” (i.e., 4 on 5-point scale) with EREFS scoring for pediatric EoE. Fleiss Kappa for all EREFS items was 0.481. For each component endoscopic finding (edema, rings, exudates, furrows, strictures), Fleiss Kappa was 0.365, 0.293, 0.548, 0.263, 0.445 respectively. Cohen’s Kappa had a median of 0.620 (IQR: 0.593, 0.704). The majority of raters rated video quality and endoscopy quality as “good” (i.e., 4 on 5-point scale). There is moderate interrater reliability in EREFS scoring for pediatric EoE. Interrater reliability was between fair to moderate for each component endoscopic finding. Intrarater reliability was good. This study shows there is room for improvement in disease scoring for pediatric EoE. This could be in the form of additional training, expert-defined conventions, or centralized reading which have reduced variability in endoscopic reporting for adult GI disease in past studies and could be used in a follow-up study to attempt to improve agreement. Additionally, incorporating EREFS into routine clinical practice may increase agreement amongst endoscopists. None None Declared
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Mo1655: DETERMINING THE PREVALENCE OF DELAYED GASTRIC EMPTYING IN PEDIATRIC PATIENTS WITH CONSTIPATION USING NUCLEAR SCINTIGRAPHY
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Mo1655: DETERMINING THE PREVALENCE OF DELAYED GASTRIC EMPTYING IN PEDIATRIC PATIENTS WITH CONSTIPATION USING NUCLEAR SCINTIGRAPHY
- Open Access
- 17 February 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (6) , e2431-e2437
Gastrointestinal Symptoms in Type 1 Diabetes: Relationship With Autoimmune and Microvascular Complications
Purpose: To assess reported rates of gastrointestinal (GI) symptoms and their association with autoimmune diseases and microvascular complications in adults and children with type 1 diabetes. Methods: The Gastrointestinal Symptom Scale was used to assess GI symptom type and severity in 2370 patients with type 1 diabetes aged 8 to 45 years evaluated as part of a clinical trial screening for celiac disease (CD). The presence and severity of GI symptoms and relationships with demographic, clinical, and other diabetes-related factors were evaluated. Results: Overall, 1368 adults (57.7%) aged 19 to 45 years and 1002 (42.3%) pediatric patients aged 8 to 18 years were studied. At least 1 GI symptom was reported in 34.1% of adults as compared with 21.7% of children (P < 0.0001). Common symptoms in children included upper and lower abdominal pain while adults more frequently reported lower GI symptoms. Participants with GI symptoms had higher hemoglobin A1c (HbA1c) levels (68 ± 14mmol/mol; 8.35 ± 1.37%) than those without symptoms (66 ± 15mmol/mol; 8.22 ± 1.40%; P = 0.041). Patients with microvascular complications (nephropathy, retinopathy, and/or neuropathy) were 1.8 times more likely to report GI symptoms (95% CI: 1.26-2.60; P < 0.01) after adjusting for age and sex. No association was observed between GI symptoms and the presence of autoimmune conditions, including thyroid and biopsy-confirmed CD (odds ratio = 1.1; 95% CI: 0.86-1.42; P = 0.45). Main Conclusions: These results highlight that GI symptoms are an important clinical morbidity and are associated with increasing age, duration of type 1 diabetes, HbA1c, and microvascular complications but not with autoimmune comorbidities including CD.
- 17 February 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (6) , e2431-e2437
Open AccessGastrointestinal Symptoms in Type 1 Diabetes: Relationship With Autoimmune and Microvascular Complications
Purpose: To assess reported rates of gastrointestinal (GI) symptoms and their association with autoimmune diseases and microvascular complications in adults and children with type 1 diabetes. Methods: The Gastrointestinal Symptom Scale was used to assess GI symptom type and severity in 2370 patients with type 1 diabetes aged 8 to 45 years evaluated as part of a clinical trial screening for celiac disease (CD). The presence and severity of GI symptoms and relationships with demographic, clinical, and other diabetes-related factors were evaluated. Results: Overall, 1368 adults (57.7%) aged 19 to 45 years and 1002 (42.3%) pediatric patients aged 8 to 18 years were studied. At least 1 GI symptom was reported in 34.1% of adults as compared with 21.7% of children (P < 0.0001). Common symptoms in children included upper and lower abdominal pain while adults more frequently reported lower GI symptoms. Participants with GI symptoms had higher hemoglobin A1c (HbA1c) levels (68 ± 14mmol/mol; 8.35 ± 1.37%) than those without symptoms (66 ± 15mmol/mol; 8.22 ± 1.40%; P = 0.041). Patients with microvascular complications (nephropathy, retinopathy, and/or neuropathy) were 1.8 times more likely to report GI symptoms (95% CI: 1.26-2.60; P < 0.01) after adjusting for age and sex. No association was observed between GI symptoms and the presence of autoimmune conditions, including thyroid and biopsy-confirmed CD (odds ratio = 1.1; 95% CI: 0.86-1.42; P = 0.45). Main Conclusions: These results highlight that GI symptoms are an important clinical morbidity and are associated with increasing age, duration of type 1 diabetes, HbA1c, and microvascular complications but not with autoimmune comorbidities including CD.
- Open Access
- 1 July 2009
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 44 (7) , A5-A8
Table of Contents
- 1 July 2009
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 44 (7) , A5-A8
Open AccessTable of Contents